Y Tse - Sino Biopharmaceutica Executive Chairlady of the Board
| SBHMY Stock | USD 9.05 0.00 0.00% |
Executive
Ms. Tse Y Y serves as Executive Chairlady of the Board of the Company since 30 June, 2015. Miss Tse the Chairlady of the Board, an Executive Director, and the Chairman of the Executive Board Committee and the Nomination Committee, respectively, of the Company. Miss Tse is also a director of CT Tianqing and the vice chairlady of Beijing Tide. She holds a Bachelor Degree of Science in Economics from the Wharton School of University of Pennsylvania. Throughout her coursework, she focused on the study of Finance and Healthcare. Previously, she worked in the investment, finance and business development departments of several companies. As a new generation business leader, Miss Tse was recognized as one of the Most Outstanding Business Women in China for 2018 by Forbe China online. Miss Tse is the daughter of Mr. Tse Ping and Ms. Cheng Cheung Ling, both being Executive Directors and substantial shareholders of the Company, and she is also a niece of each of Mr. Tse Hsin, an Executive Director of the Company, Ms. Chia Fai, Miss Tse Wun, and Mr. Tse Hsuan, Johnny, all being senior management of the Company. since 2015.
| Age | 31 |
| Tenure | 9 years |
| Phone | 852 2802 9886 |
| Web | https://www.sinobiopharm.com |
Sino Biopharmaceutica Management Efficiency
The company has return on total asset (ROA) of 0.0451 % which means that it generated a profit of $0.0451 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2908 %, meaning that it generated $0.2908 on every $100 dollars invested by stockholders. Sino Biopharmaceutica's management efficiency ratios could be used to measure how well Sino Biopharmaceutica manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Scott Youmans | Tarsus Pharmaceuticals | N/A | |
| Ryan Witt | RenovoRx | N/A | |
| Matthew Metivier | Nuvalent | N/A | |
| Neel Anand | Kezar Life Sciences | N/A | |
| Stefanie JD | Genfit | 42 | |
| Patrick MD | Centessa Pharmaceuticals PLC | N/A | |
| Sakina SayahJeanne | Genfit | 52 | |
| FACS FACS | Eledon Pharmaceuticals | N/A | |
| Lindsay Young | Tempest Therapeutics | N/A | |
| Jared JD | Entrada Therapeutics | N/A | |
| MS MD | Opthea | 49 | |
| John Brozek | Genfit | 47 | |
| Samuel MD | Tempest Therapeutics | 58 | |
| Cara Miller | Tarsus Pharmaceuticals | N/A | |
| Fang Li | Opthea | 60 | |
| Pattie Chiang | Kezar Life Sciences | N/A | |
| Leesa Gentry | RenovoRx | 54 | |
| Harris Rotman | Centessa Pharmaceuticals PLC | N/A | |
| Meriam Kabbaj | Genfit | 50 | |
| Henry Pelish | Nuvalent | N/A | |
| Peter MBA | Opthea | 52 | |
Management Performance
| Return On Equity | 0.29 | |||
| Return On Asset | 0.0451 |
Sino Biopharmaceutical Leadership Team
Elected by the shareholders, the Sino Biopharmaceutica's board of directors comprises two types of representatives: Sino Biopharmaceutica inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sino. The board's role is to monitor Sino Biopharmaceutica's management team and ensure that shareholders' interests are well served. Sino Biopharmaceutica's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sino Biopharmaceutica's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Cheung Cheng, Executive Vice Chairlady of the Board | ||
| Fai Chia, Assistant to the President and Vice President | ||
| Wei Ye, Assistant President General Manager - R&D Department | ||
| Ping Tse, CEO, Executive Director | ||
| Mingqin Li, Vice President Executive Director | ||
| Wun Tse, Assistant to the President | ||
| Zhoushan Tian, Executive Director | ||
| Y Tse, Executive Chairlady of the Board | ||
| Hsin Tse, Vice President Executive Director | ||
| Eric Tse, CEO Director |
Sino Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Sino Biopharmaceutica a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.29 | |||
| Return On Asset | 0.0451 | |||
| Profit Margin | 0.29 % | |||
| Operating Margin | 0.16 % | |||
| Current Valuation | 10.34 B | |||
| Shares Outstanding | 940.69 M | |||
| Price To Earning | 8.95 X | |||
| Price To Book | 2.53 X | |||
| Price To Sales | 0.41 X | |||
| Revenue | 26.86 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Sino Pink Sheet Analysis
When running Sino Biopharmaceutica's price analysis, check to measure Sino Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sino Biopharmaceutica is operating at the current time. Most of Sino Biopharmaceutica's value examination focuses on studying past and present price action to predict the probability of Sino Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sino Biopharmaceutica's price. Additionally, you may evaluate how the addition of Sino Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.